Periodontal disease - a chronic inflammatory process of the periodontal tissue. Oral Health Periodontitis
Conditions
Interventions
Osteoarthritic patients were prescribed 800 mg of oral CS once daily (Condrosan®, Bioiberica, S.A., Spain) for this disease, before being eligible to enter the study. Once enrolled were asked not to c
Sponsors
Rheumatology Service, Hospital del Mar
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients > 40 years 2. Fulfilled the American College of Rheumatology classification criteria for clinical knee, hand or hip OA 3. Initiated CS treatment for their OA 4. Had PD of any severity grade as assessed by the Community Periodontal Index Treatment Needs (CPITN) 5. Had PD of grades II, III or IV as assessed with the Löe and Silness gingival index
Exclusion criteria
Exclusion criteria: 1. Uncompensated cardiopathy; 2. Impaired renal or liver function; 3. Uncompensated asthma; severe infection 4. Human Immunodeficiency Virus 5. History of alcohol or substance abuse 6. Any currently uncompensated psychiatric disorder 7. Fibromyalgia 8. Uncompensated thyroid disease 9. Having a contraindication to CS use
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patients were assessed at baseline 3, 6, 9, and 12 months. 1. Assessment of the periodontal pocket is calculated with CPITN in the more affected dental piece in each sextant of the oral cavity. 2. Gingival inflammation status evaluation Löe and Silness index is recorded from Ramfjord dental pieces (1.6, 2.1,2.4, 3.6, 4.1, 4.4). In addition, for the establishment of the bone dental support status an orthopantomography (Siemens Ortophos orthopantomograph, PACS software, image scale 1:1) is carried out at baseline, month 6, and end of follow up (month 12). The loss of bone was assessed through the measurement in mm of the distance between the cemento-enamel junction and the bone margin in the 3 most affected teeth. The pattern of alveolar bone destruction is assessed by a unique expert dentist, by quantifying the vertical defects, which reflex the slow and chronic lesions; and well as horizontal defects, more related to the teeth support and hence in the tooth loss. | — |
Secondary
| Measure | Time frame |
|---|---|
| Biomarkers of inflammation (IL-1, IL-18, TNF-alfa, and PGE2) matrix degradation (MMP-8) and bone metabolism markers (osteopontin, OPG and RANKL) are measured in the saliva collected at baseline, 3,6,9 and 12 months. The biomarkers were measured by means of custom made protein microarray except for PGE2 levels that were quantified using an enzyme-linked immunosorbent assay kit. | — |
Countries
Spain
Outcome results
None listed